Drug Combo Fails to Cut Fracture Risk in Brittle Bone Disease

(MedPage Today) — SEATTLE — Treating osteogenesis imperfecta with the parathyroid hormone teriparatide followed by zoledronic acid, a bisphosphonate, failed to reduce the risk of fractures compared with standard treatment, initial results of…

Source link : https://www.medpagetoday.com/meetingcoverage/asbmr/117377

Author :

Publish date : 2025-09-09 18:15:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

Drug Combo Fails to Cut Fracture Risk in Brittle Bone Disease

How cosmic events may have influenced hominin evolution

‘This Will Get People Killed’: Experts Alarmed by CDC’s Sharp Political Turn

Related Posts

Many People Without Celiac Disease Report Gluten, Wheat Sensitivity

Mixed Results With Metformin for Men on ADT for Prostate Cancer

Difficult-to-Treat Rheumatoid Arthritis: Is Prevention Feasible?

Dual GIP/GLP-1 Drug Linked to Fewer Deaths in Real-World Liver Disease Study

Modestly Higher Risk for Autoimmune Disease Linked to HT

Delaying Gallbladder Removal After Bile Duct Stones May Be Riskier

Many People Without Celiac Disease Report Gluten, Wheat Sensitivity

Mixed Results With Metformin for Men on ADT for Prostate Cancer

Difficult-to-Treat Rheumatoid Arthritis: Is Prevention Feasible?

Dual GIP/GLP-1 Drug Linked to Fewer Deaths in Real-World Liver Disease Study

Modestly Higher Risk for Autoimmune Disease Linked to HT

Delaying Gallbladder Removal After Bile Duct Stones May Be Riskier

First 7-Year Report of Low-Risk TAVR Reassures, With Finish Line Now in Sight

Pre-op Immunotherapy for Head and Neck Cancer Rising

Categories

Archives